UCB (UCB.VI)

Executive Summary

UCB is a global biopharmaceutical company headquartered in Belgium, specializing in neurology and immunology. With a robust pipeline of over 600 drug candidates and 12 approved products, the company addresses severe unmet medical needs in epilepsy, Parkinson's disease, allergies, and autoimmune conditions. UCB's recent strategic focus on innovative biologics and targeted therapies has driven growth, with key products such as Briviact (antiepileptic) and Cimzia (anti-TNF for autoimmune diseases) contributing to a market capitalization of approximately $46 billion. The company's commitment to R&D is evident from its substantial investment in early-stage research and partnerships, positioning it as a leader in CNS and inflammatory disease treatment.

Upcoming Catalysts (preview)

• Q2 2026Bimekizumab (bimekizumab) potential approval for psoriatic arthritis and other indications85% success
• Q1 2026Rozanolixizumab (rozanolixizumab) regulatory decision for generalized myasthenia gravis70% success
• Q4 2026Dapirolizumab pegol (dapirolizumab) Phase 3 data in systemic lupus erythematosus60% success